Company name: GeneDesign, Inc.
Founded: December, 2000
Capital: 50,000 thousand Yen
Head Office/Research Institute
<Location> 7-7-29 Saitoasagi,Ibaraki,Osaka 567-0085,JAPAN
<Phone> +81-72-640-5180 <FAX> +81-72-640-5181
Number of employees: 56
E-mail address for inquiry:
Following recent advances in genetic
engineering, development of new pharmaceutical products for the treatment of
various diseases, previously difficult to treat, has been carried out. Research and development are active across
the world about the promising next-generation drugs such as those making use of
nucleic acid (nucleic acid drucs) for gene expression regulation (antisense,
decoy, siRNA, etc.), inhibition of the function for specific target molecules
with aptamers, and so on.
GeneDesign, Inc. began its operation by custom synthesis of oligonucleotides
for use in research. Later, the company introduced latest
technology and patent licenses from Osaka University Grade School of
Pharmaceutical Sciences, Osaka University Graduate School of Medicine, Research
Institute for Microbial Diseases (Osaka University) and RIKEN, and has been
actively engaged in development of new products using new nucleic acid
production technologies. To date, the
company has provided unique nucleic acid materials such as BNA (bridged nucleic
acid), ribbon-type decoy nucleic acid, ICON Probe and Chum-RNA, contributing to
development of new technologies (related to pharmaceutical products, diagnostic
technology, biotechnology research, etc.) based on gene-related technology.
At present, the demand to various synthetic
oligonucleotides is being expanded from the culture cell level to animal study
materials and clinical trials.
GeneDesign Inc. has established a system capable of providing a wide
range of oligonucleotides encompassing used in research and for clinical trials
and has been actively conducting research and development in order to become an
enterprise which can contribute greatly to commercialization of nucleic
acid-based medicines and diagnostic systems.
We will continue our efforts for development
of nucleic acid-based new-generation medicines and diagnostic reagents, with a
goal set at becoming an enterprise contributing to human welfare and health
through nucleic acid technology development.